RU2020119065A - Маркеры болезни фарбера и их применения - Google Patents
Маркеры болезни фарбера и их применения Download PDFInfo
- Publication number
- RU2020119065A RU2020119065A RU2020119065A RU2020119065A RU2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A
- Authority
- RU
- Russia
- Prior art keywords
- cd11b
- mhcii
- level
- farber
- disease
- Prior art date
Links
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 title claims 20
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 50
- 102100022338 Integrin alpha-M Human genes 0.000 claims 50
- 238000000034 method Methods 0.000 claims 20
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 19
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 19
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 18
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 13
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 6
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101000975753 Homo sapiens Acid ceramidase Proteins 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 102000047408 human ASAH1 Human genes 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648775P | 2018-03-27 | 2018-03-27 | |
| US62/648,775 | 2018-03-27 | ||
| PCT/IB2019/000290 WO2019186272A1 (en) | 2018-03-27 | 2019-03-22 | Farber disease markers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020119065A true RU2020119065A (ru) | 2022-04-27 |
Family
ID=66530353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020119065A RU2020119065A (ru) | 2018-03-27 | 2019-03-22 | Маркеры болезни фарбера и их применения |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3775924A1 (https=) |
| JP (2) | JP2021516757A (https=) |
| KR (2) | KR20200136367A (https=) |
| CN (2) | CN111971562A (https=) |
| AU (1) | AU2019244477A1 (https=) |
| BR (1) | BR112020016435A2 (https=) |
| CA (1) | CA3090354A1 (https=) |
| CL (1) | CL2020002105A1 (https=) |
| CO (1) | CO2020010043A2 (https=) |
| IL (2) | IL311212A (https=) |
| MX (1) | MX2020008377A (https=) |
| PH (1) | PH12020551206A1 (https=) |
| RU (1) | RU2020119065A (https=) |
| SG (1) | SG11202007508TA (https=) |
| WO (1) | WO2019186272A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020152532A1 (en) * | 2019-01-23 | 2020-07-30 | Enzyvant Therapeutics Gmbh | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
| US20240180982A1 (en) * | 2021-03-29 | 2024-06-06 | University College Cardiff Consultants Limited | Modified adenovirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1995001164A1 (en) | 1993-06-30 | 1995-01-12 | Genentech, Inc. | Method for preparing liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| CA2905449C (en) | 2013-03-14 | 2024-09-10 | Icahn School Of Medicine At Mount Sinai | THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE |
| EP3115786A1 (en) * | 2015-07-08 | 2017-01-11 | Centogene AG | Method for the diagnosis of farber's disease |
-
2019
- 2019-03-22 CA CA3090354A patent/CA3090354A1/en active Pending
- 2019-03-22 CN CN201980008575.9A patent/CN111971562A/zh active Pending
- 2019-03-22 JP JP2020543884A patent/JP2021516757A/ja active Pending
- 2019-03-22 RU RU2020119065A patent/RU2020119065A/ru unknown
- 2019-03-22 EP EP19723847.0A patent/EP3775924A1/en not_active Withdrawn
- 2019-03-22 KR KR1020207023065A patent/KR20200136367A/ko not_active Ceased
- 2019-03-22 IL IL311212A patent/IL311212A/en unknown
- 2019-03-22 MX MX2020008377A patent/MX2020008377A/es unknown
- 2019-03-22 CN CN202311688835.6A patent/CN118112249A/zh active Pending
- 2019-03-22 AU AU2019244477A patent/AU2019244477A1/en not_active Abandoned
- 2019-03-22 BR BR112020016435-6A patent/BR112020016435A2/pt unknown
- 2019-03-22 KR KR1020247022597A patent/KR20240111011A/ko not_active Ceased
- 2019-03-22 SG SG11202007508TA patent/SG11202007508TA/en unknown
- 2019-03-22 WO PCT/IB2019/000290 patent/WO2019186272A1/en not_active Ceased
-
2020
- 2020-07-30 IL IL276420A patent/IL276420A/en unknown
- 2020-08-07 PH PH12020551206A patent/PH12020551206A1/en unknown
- 2020-08-14 CO CONC2020/0010043A patent/CO2020010043A2/es unknown
- 2020-08-14 CL CL2020002105A patent/CL2020002105A1/es unknown
-
2023
- 2023-08-03 JP JP2023127159A patent/JP2023159164A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111971562A (zh) | 2020-11-20 |
| JP2021516757A (ja) | 2021-07-08 |
| WO2019186272A1 (en) | 2019-10-03 |
| EP3775924A1 (en) | 2021-02-17 |
| AU2019244477A1 (en) | 2020-06-25 |
| CN118112249A (zh) | 2024-05-31 |
| IL276420A (en) | 2020-09-30 |
| JP2023159164A (ja) | 2023-10-31 |
| CA3090354A1 (en) | 2019-10-03 |
| MX2020008377A (es) | 2020-09-25 |
| PH12020551206A1 (en) | 2021-04-19 |
| BR112020016435A2 (pt) | 2020-12-15 |
| SG11202007508TA (en) | 2020-09-29 |
| CL2020002105A1 (es) | 2020-12-04 |
| IL311212A (en) | 2024-05-01 |
| KR20200136367A (ko) | 2020-12-07 |
| CO2020010043A2 (es) | 2020-11-10 |
| KR20240111011A (ko) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lotz et al. | Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis | |
| Kerr et al. | Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition | |
| ES2310931T3 (es) | Analogos de interferon alfa humano de baja toxicidad. | |
| ES2279575T3 (es) | Analogos de peptidos derivados de receptores del factor de necrosis tumoral. | |
| US20200188471A1 (en) | Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis | |
| Wondimu et al. | Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis | |
| MX2013000542A (es) | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. | |
| RU2020119065A (ru) | Маркеры болезни фарбера и их применения | |
| JPH11506737A (ja) | 小細胞肺ガンを治療または検出するためのコノトキシンペプチドｕ００２およびｍｉｉの使用 | |
| JP2021516757A5 (https=) | ||
| HRP20030215A2 (en) | Chemokine mutants in the tratment of multiple sclerosis | |
| ATE191502T1 (de) | Corticotropinauslösefaktor-bindendes protein | |
| JPH07563B2 (ja) | 好酸球増加症の予防または鎮静用薬剤 | |
| KR20160109561A (ko) | 관절염 예방 또는 치료용 약학적 조성물 | |
| Labuda et al. | Tick-borne encephalitis virus activity in Styria, Austria | |
| JPWO2019186272A5 (https=) | ||
| CN1421459A (zh) | 人源化抗cd3单克隆抗体 | |
| Zhu et al. | Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice | |
| JPH0544930B2 (https=) | ||
| CN103333236B (zh) | 一种优秀冰雪运动员血管紧张素转化酶部分多肽多克隆抗体制备方法 | |
| McIrvine et al. | Fatal infection in mice after injection of immunosuppressive serum fractions from surgical patients | |
| Yang et al. | Identification of the mouse calcium‐binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni‐induced granulomas: biochemical and functional characterization | |
| CN102250239B (zh) | 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用 | |
| CN102250234B (zh) | 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用 | |
| van Mook et al. | A rare case of disseminated actinomycosis caused by Actinomyces meyeri |